Skip to content

The Effect of Green Tea and Vitamin C on Skin Health

The Effect of Dietary Bioactive Compounds on Skin Health in Humans in Vivo

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01032031
Enrollment
95
Registered
2009-12-15
Start date
2009-03-31
Completion date
2012-08-31
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Cancer

Keywords

Green tea, Vitamin C, Ultraviolet radiation, Inflammation, Photoageing

Brief summary

There is little information on the effect of oral bioactive compounds on human skin clinically despite evidence of a beneficial effect from laboratory studies. The aim of this study is to examine the effect of oral bioactive compounds (green tea and vitamin C) on the health of human skin by measuring markers of skin health directly and skin nutrient uptake.

Detailed description

There is little information on the effect of oral catechin, a nutritionally relevant bioactive compound, on skin health in humans in vivo despite considerable evidence for protective effects in experimental studies. Vitamin C is essential for skin health and stabilises catechins in the gut lumen. Ultraviolet radiation (UVR) in sunlight is a key environmental stressor impacting on skin health. Effects include acute inflammation and longer term photodamage. OBJECTIVE: To examine the protective effect of catechin and vitamin C on UVR-induced inflammation. STUDY DESIGN (1) A double-blind randomised controlled nutritional study in 50 healthy volunteers. Volunteers will receive 3 months dietary supplement with high dose bioactive (n=25),or placebo (n=25). The aim is to quantify the influence of catechin/vitamin C on: 1. UVR-induced inflammation 2. Leukocyte infiltration 3. Inflammatory mediators 4. Markers of photoageing 5. DNA damage 6. Bioavailability will also be assessed (2) Bioavailability of catechin and vitamin C in skin and blood. Volunteers will receive active dietary supplement. Blood and urine samples will be taken over a period of 6 hours to determine blood bioavailability. Skin biopsies will also be taken to assess skin bioavailability. Volunteers will then receive 3 months of active dietary supplement followed by repeated sampling.

Interventions

DIETARY_SUPPLEMENTGreen tea + vitamin C high dose

One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months

DIETARY_SUPPLEMENTPlacebo capsule

One capsule daily for 3 months

Sponsors

University of Leeds
CollaboratorOTHER
University of Bradford
CollaboratorOTHER
University of Manchester
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy adults * Sun-reactive skin type I / II

Exclusion criteria

* History of skin cancer * History of a photosensitivity disorder * History of a generalised skin disorder * Sunbathing (including sunbeds) in the past 3 months * Pregnancy * Taking photoactive medicine * Drink tea \> 2 cups/day * Taking nutritional supplements

Design outcomes

Primary

MeasureTime frameDescription
Change in the minimum erythemal dose (MED) of ultraviolet radiation.3 monthsThe UV minimum erythemal dose (MED) will be determined for each study volunteer before and after nutritional supplementation to examine if the intervention can increase the MED and therefore protect against UV-induced erythema.

Secondary

MeasureTime frameDescription
Intergroup comparison of inflammatory mediators (cytokines/chemokines) in skin biopsy sections and blister fluid.3 months
Intergroup comparison of histological biomarkers (leucocytes, markers of photoageing, DNA damage) in skin biopsy sections.3 months
Nutrient (polyphenol) bioavailability in samples of skin, blood and urine.3 monthsBioavailability will be assessed in volunteers participating in both the first (RCT) and second (non-randomised bioavailability) parts of the study.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026